IL144755A0 - Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles - Google Patents

Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Info

Publication number
IL144755A0
IL144755A0 IL14475500A IL14475500A IL144755A0 IL 144755 A0 IL144755 A0 IL 144755A0 IL 14475500 A IL14475500 A IL 14475500A IL 14475500 A IL14475500 A IL 14475500A IL 144755 A0 IL144755 A0 IL 144755A0
Authority
IL
Israel
Prior art keywords
vehicles
single phase
stable non
aqueous single
formulations utilizing
Prior art date
Application number
IL14475500A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144755(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL144755A0 publication Critical patent/IL144755A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IL14475500A 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles IL144755A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08
PCT/US2000/002772 WO2000045790A2 (en) 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Publications (1)

Publication Number Publication Date
IL144755A0 true IL144755A0 (en) 2002-06-30

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14475500A IL144755A0 (en) 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Country Status (22)

Country Link
EP (2) EP1152749B1 (de)
JP (1) JP4861551B2 (de)
KR (2) KR20080045300A (de)
CN (1) CN1232244C (de)
AR (1) AR029613A1 (de)
AT (2) ATE537811T1 (de)
AU (1) AU775904B2 (de)
CA (1) CA2361424C (de)
CO (1) CO5140096A1 (de)
CY (1) CY1119950T1 (de)
DE (1) DE60027272T2 (de)
DK (1) DK1666026T4 (de)
ES (2) ES2261190T3 (de)
HK (2) HK1041451B (de)
HU (1) HUP0200202A3 (de)
IL (1) IL144755A0 (de)
NO (1) NO20013861L (de)
NZ (1) NZ513441A (de)
PT (2) PT1152749E (de)
TW (2) TW200730199A (de)
WO (1) WO2000045790A2 (de)
ZA (1) ZA200106443B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2508124A1 (en) * 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
JP2006522133A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
CN100548411C (zh) 2003-03-31 2009-10-14 精达制药公司 设置有内部压力释放部件的渗透泵
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
EP2547323B1 (de) 2010-03-17 2016-01-27 Novaliq GmbH Pharmazeutische zusammensetzung zur behandlung erhöhten intraokulardrucks
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
EP2714008B1 (de) 2011-05-25 2016-12-14 Novaliq GmbH Pharmazeutische zusammensetzung zur verabreichung an nägel
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
JP6503349B2 (ja) 2013-07-23 2019-04-17 ノバリック ゲーエムベーハー 安定化された抗体組成物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
EP3495023B1 (de) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorierte verbindungen und deren zusammensetzungen
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
EP3515420B1 (de) 2016-09-22 2023-11-08 Novaliq GmbH Pharmazeutische zusammensetzung zur verwendung in der therapie von blepharitis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (de) 2017-05-12 2020-03-18 Novaliq GmbH Pharmazeutische zusammensetzungen mit semifluorierten alkanen zur behandlung von beschwerden im zusammenhang mit kontaktlinsen
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
ES2974839T3 (es) 2018-10-12 2024-07-01 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad de ojos secos
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
AU3136293A (en) † 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
WO1994021262A1 (en) * 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
ATE149349T1 (de) † 1993-06-25 1997-03-15 Alza Corp Einarbeitung eines poly-n-vinylamids in ein transdermales system
CA2167526A1 (en) † 1993-09-29 1995-04-06 Lina Tormen Taskovich Monoglyceride/lactate ester permeation enhancer
WO1996012495A1 (fr) * 1994-10-24 1996-05-02 Nikken Chemicals Co., Ltd Preparation administrable par voie percutanee
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
PL184820B1 (pl) * 1995-06-06 2002-12-31 Hoffmann La Roche Dawka jednostkowa kompozycji farmaceutycznej do leczenia chorób wywoływanych przez HIV
UA48973C2 (uk) † 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5904935A (en) † 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ES2227707T3 (es) † 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
DE69718037T2 (de) † 1996-10-24 2003-07-10 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
AU3481600A (en) 2000-08-25
TWI292716B (en) 2008-01-21
HK1041451B (zh) 2006-12-01
HUP0200202A2 (hu) 2002-05-29
JP4861551B2 (ja) 2012-01-25
CY1119950T1 (el) 2018-12-12
HUP0200202A3 (en) 2009-08-28
NO20013861D0 (no) 2001-08-08
PT1152749E (pt) 2006-08-31
EP1152749A2 (de) 2001-11-14
DK1666026T4 (da) 2015-05-04
EP1666026A2 (de) 2006-06-07
ES2261190T3 (es) 2006-11-16
EP1666026A3 (de) 2007-08-08
WO2000045790A2 (en) 2000-08-10
CA2361424C (en) 2009-04-28
KR20080045300A (ko) 2008-05-22
EP1666026B1 (de) 2011-12-21
NZ513441A (en) 2004-01-30
HK1094528A1 (en) 2007-04-04
TW200730199A (en) 2007-08-16
ES2379471T5 (es) 2015-05-26
CO5140096A1 (es) 2002-03-22
AU775904B2 (en) 2004-08-19
KR100858856B1 (ko) 2008-09-17
WO2000045790A3 (en) 2000-12-07
AR029613A1 (es) 2003-07-10
ATE322889T1 (de) 2006-04-15
EP1666026B2 (de) 2015-02-25
ES2379471T3 (es) 2012-04-26
CN1232244C (zh) 2005-12-21
ATE537811T1 (de) 2012-01-15
EP1152749B1 (de) 2006-04-12
NO20013861L (no) 2001-09-20
JP2002536315A (ja) 2002-10-29
KR20010101842A (ko) 2001-11-14
CA2361424A1 (en) 2000-08-10
ZA200106443B (en) 2002-08-06
CN1339962A (zh) 2002-03-13
PT1666026E (pt) 2012-03-15
DK1666026T3 (da) 2012-04-10
HK1041451A1 (en) 2002-07-12
DE60027272T2 (de) 2007-01-25
DE60027272D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
HUP0200202A3 (en) Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU6694600A (en) Cosmetic compositions with self-warming component
HK1090834A1 (en) Non-aqueous single phase vehicles and formulations utilizing such vehicles
AU6734700A (en) Cosmetics
PL339919A1 (en) Stable cosmetic compositions
AU1916599A (en) Sachet formulations
GB0021406D0 (en) Formulation
GB9909323D0 (en) Phase modulator
AU9311398A (en) Stable anhydrous formulation
GB9817354D0 (en) Liquid formulation
AU7373000A (en) Cosmetic compositions
AU5282800A (en) Stable voltage reference circuit
AUPQ002999A0 (en) Non-aqueous shampoo composition
AU6629900A (en) Cosmetics
AU2176001A (en) Cosmetic composition
AU5107400A (en) Heat-evolving cosmetics
AU5770100A (en) Cosmetic compositions
HUP0202151A3 (en) Stable formulation containing fumagillin
GB9810655D0 (en) Stable ammonium compositions
AU4604599A (en) Stable quaternary ammonium compositions
AU5771200A (en) Cosmetic compositions
PL345768A1 (en) Liquid formulation
AU5771000A (en) Cosmetic compositions
AU4579400A (en) Packaged cosmetics
GB9902236D0 (en) Formulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired